Anti-CD5 CAR-T cells with a tEGFR safety switch exhibit potent toxicity control

Blood Cancer J. 2024 Jun 18;14(1):98. doi: 10.1038/s41408-024-01082-y.

Haolong Lin^#^{1

2}, Jiali Cheng^#^{1

2}, Li Zhu^{1

2}, Yuhao Zeng³, Zhenyu Dai⁴, Yicheng Zhang^{1

2}, Xiaojian Zhu^{5

6}, Wei Mu^{7

8}

¹ Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, 430030, China.
² Immunotherapy Research Center for Hematologic Diseases of Hubei Province, Wuhan, Hubei, 430030, China.
³ Department of Internal Medicine, Cleveland Clinic, Akron General, Akron, OH, USA.
⁴ Division of Blood and Marrow Transplantation and Cellular Therapy, Department of Medicine, Stanford University, Stanford, CA, USA.
⁵ Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, 430030, China. zhuxiaojian@hust.edu.cn.
⁶ Immunotherapy Research Center for Hematologic Diseases of Hubei Province, Wuhan, Hubei, 430030, China. zhuxiaojian@hust.edu.cn.
⁷ Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, 430030, China. muweicelltherapy@163.com.
⁸ Immunotherapy Research Center for Hematologic Diseases of Hubei Province, Wuhan, Hubei, 430030, China. muweicelltherapy@163.com.

^# Contributed equally.

No abstract available

Publication types